Huaren Pharmaceutical Co., Ltd. (SHE:300110)
China · Delayed Price · Currency is CNY 2.880
-0.060 (-2.04%)
May 21, 2026, 3:04 PM CST
Huaren Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,312 | 1,305 | 1,338 | 1,540 | 1,576 | 1,561 |
Other Revenue | 16.17 | 16.17 | 15.41 | 96.11 | 43.04 | - |
| 1,328 | 1,321 | 1,353 | 1,636 | 1,619 | 1,561 | |
Revenue Growth (YoY) | 6.24% | -2.34% | -17.30% | 1.03% | 3.76% | 18.55% |
Cost of Revenue | 878 | 864.42 | 885.61 | 940.42 | 923.59 | 800.71 |
Gross Profit | 449.95 | 457.04 | 467.55 | 695.83 | 695.9 | 760.15 |
Selling, General & Admin | 239.62 | 240.17 | 242.68 | 310.45 | 330.23 | 399.91 |
Research & Development | 67.44 | 67.83 | 72.29 | 68.68 | 55.3 | 63.68 |
Other Operating Expenses | 19.91 | 18.34 | 12.68 | 20.06 | 27.13 | 27.73 |
Operating Expenses | 328.79 | 335.7 | 337.5 | 350.99 | 451.32 | 533.51 |
Operating Income | 121.16 | 121.33 | 130.05 | 344.84 | 244.58 | 226.64 |
Interest Expense | -40.12 | -41.97 | -54.32 | -61.51 | -64.16 | -63.14 |
Interest & Investment Income | 5.25 | 5.34 | 0.93 | 3 | 4.77 | 1.8 |
Currency Exchange Gain (Loss) | -0.1 | -0.1 | 0.14 | 0.24 | 0.15 | -0.07 |
Other Non Operating Income (Expenses) | -12.82 | -14.04 | -1,345 | -64.89 | -16.15 | -22.13 |
EBT Excluding Unusual Items | 73.37 | 70.56 | -1,268 | 221.68 | 169.18 | 143.1 |
Impairment of Goodwill | -524.72 | -524.72 | -87.43 | -6.25 | -0.35 | - |
Gain (Loss) on Sale of Investments | -0.02 | - | -1.17 | - | -1.39 | -0.87 |
Gain (Loss) on Sale of Assets | -0.35 | 0.01 | 0.02 | 4.35 | 13.86 | -0.17 |
Asset Writedown | -5.2 | -6.29 | -0.14 | -0.78 | -6.34 | - |
Other Unusual Items | -0.21 | 1.49 | 0.71 | 11.51 | 30.89 | 8.2 |
Pretax Income | -457.12 | -458.94 | -1,356 | 230.51 | 205.86 | 150.26 |
Income Tax Expense | 2.01 | 0.45 | 7.08 | 37.09 | 24.56 | 16.21 |
Earnings From Continuing Operations | -459.13 | -459.39 | -1,363 | 193.42 | 181.3 | 134.05 |
Minority Interest in Earnings | -3.84 | -3.51 | -5.65 | -5.36 | -0.52 | -3.65 |
Net Income | -462.97 | -462.9 | -1,368 | 188.06 | 180.78 | 130.4 |
Net Income to Common | -462.97 | -462.9 | -1,368 | 188.06 | 180.78 | 130.4 |
Net Income Growth | - | - | - | 4.03% | 38.63% | 37.81% |
Shares Outstanding (Basic) | 1,183 | 1,182 | 1,182 | 1,182 | 1,182 | 1,185 |
Shares Outstanding (Diluted) | 1,183 | 1,182 | 1,182 | 1,182 | 1,182 | 1,185 |
Shares Change (YoY) | 0.14% | -0.01% | 0.01% | 0.04% | -0.33% | 0.23% |
EPS (Basic) | -0.39 | -0.39 | -1.16 | 0.16 | 0.15 | 0.11 |
EPS (Diluted) | -0.39 | -0.39 | -1.16 | 0.16 | 0.15 | 0.11 |
EPS Growth | - | - | - | 3.99% | 39.09% | 37.50% |
Free Cash Flow | 279.79 | 341.25 | 297.67 | 259.74 | 175.65 | -606.38 |
Free Cash Flow Per Share | 0.24 | 0.29 | 0.25 | 0.22 | 0.15 | -0.51 |
Dividend Per Share | - | - | - | 0.021 | 0.021 | 0.018 |
Dividend Growth | - | - | - | - | 16.67% | 20.00% |
Gross Margin | 33.88% | 34.59% | 34.55% | 42.53% | 42.97% | 48.70% |
Operating Margin | 9.12% | 9.18% | 9.61% | 21.07% | 15.10% | 14.52% |
Profit Margin | -34.86% | -35.03% | -101.13% | 11.49% | 11.16% | 8.36% |
Free Cash Flow Margin | 21.07% | 25.82% | 22.00% | 15.87% | 10.85% | -38.85% |
EBITDA | 225.14 | 228.1 | 247.95 | 470.74 | 393.17 | 361.03 |
EBITDA Margin | 16.95% | 17.26% | 18.32% | 28.77% | 24.28% | 23.13% |
D&A For EBITDA | 103.98 | 106.76 | 117.9 | 125.9 | 148.59 | 134.39 |
EBIT | 121.16 | 121.33 | 130.05 | 344.84 | 244.58 | 226.64 |
EBIT Margin | 9.12% | 9.18% | 9.61% | 21.07% | 15.10% | 14.52% |
Effective Tax Rate | - | - | - | 16.09% | 11.93% | 10.79% |
Revenue as Reported | 1,328 | 1,321 | 1,353 | 1,636 | 1,619 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.